Loading clinical trials...
Loading clinical trials...
A Double-blinded, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of AION-301 Administered by Intravenous Infusion for the Treatment of Participants With Stage 3 Chronic Kidney Disease
Conditions
Interventions
AION-301
Placebo
Locations
2
United States
SouthCoast Research Center, Inc.
Miami, Florida, United States
University of Miami, Leonard M. Miller School of Medicine
Miami, Florida, United States
Start Date
January 23, 2025
Primary Completion Date
January 1, 2027
Completion Date
May 1, 2027
Last Updated
April 1, 2026
NCT06925217
NCT06939816
NCT06933108
NCT06956872
NCT06394544
NCT06760650
Lead Sponsor
AION Healthspan, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions